Anticoagulation Agents

ApprovedSmall molecule

IInari Medical

Anticoagulation Agents is one of 93 small molecule programs targeting Venous thrombosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThrombosisActive, not recruiting

Esophageal VaricesActive, not recruiting

Atrial FibrillationActive, not recruiting

COVID-19Active, not recruiting

Venous ThrombosisApproved

Active, not recruiting

Esophageal VaricesPreclinical

Active, not recruiting

Atrial FibrillationPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Anticoagulation Agents

IInari Medical

Approved

1 2

Stivarga

Bayer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Singulair

AstraZeneca

Preclinical

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—8

Piperacillin/tazobactam

Pfizer

Preclinical

1 9

Conventional

PPopulation Health Research Institute

Preclinical

1 10

DAS181

AAnsun Biopharma, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Atrial Fibrillation

NCT06045858

Q3 2028

Post-ApprovalRecruiting

Venous Thrombosis

NCT07352358

Clinical

Trials by Indication[1]

Venous thrombosis1 trial

Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis

Recruiting·XXuanwu Hospital, Beijing·Phase 4·NCT07352358·72 enrolled

Esophageal Varices1 trial

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Unknown status·SShanghai Zhongshan Hospital··NCT04527666·40 enrolled

Atrial Fibrillation1 trial

Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)

Not yet recruiting·UUniversity Hospital, Caen·Phase 3·NCT06045858·178 enrolled

Anticoagulation1 trial

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06057467·2,351 enrolled

Hemodynamic1 trial

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

Completed·IInari Medical··NCT03761173·1,200 enrolled

2 more indications

ESS1 trial

The PEERLESS II Study

Recruiting·IInari Medical·N/A·NCT06055920·1,200 enrolled

COVID-191 trial

Hamburg Edoxaban for Anticoagulation in COVID-19 Study

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 3·NCT04542408·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Anticoagulation Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anticoagulation Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anticoagulation Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inari Medical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IInari Medical

Anticoagulation Agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Venous thrombosis1 trial

Esophageal Varices1 trial

Atrial Fibrillation1 trial

Anticoagulation1 trial

Hemodynamic1 trial

ESS1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News